Table 1.
New York City April 2009 – December 2018 cohort characteristics and proportions treated for HSIL, proportions presenting for surveillance within 18 months of treatment of HSIL.
|
| ||||
|---|---|---|---|---|
| Outcome: Treatment | ||||
|
| ||||
| Characteristic (n=1,179) | Treatment (n=684) | No Treatment (n=495) | Unadjusted OR** (95% CI) | Adjusted OR** (95% CI) |
|
| ||||
| Age *** | ||||
| Mean (SD): 42.3 (11.5) | 41.9 (11.4) | 42.9 (11.5) | 0.87 (0.68 – 1.12) | 0.89 (0.68 – 1.17) |
|
| ||||
| Sexual Practices | ||||
| Heterosexual (n=136, 11.5%) | 65 (47.8%) | 71 (52.2%) | 1.60 (1.12 – 2.28) | 1.15 (0.78 – 1.70) |
| MSM (n=1043, 88.5%) | 619 (59.4%) | 424 (40.7%) | ||
|
| ||||
| Race/Ethnicity | ||||
| White (n=425, 36.0%) | 278 (65.4%) | 147 (34.6%) | 1 | 1 |
| Black (n=269, 22.8%) | 127 (47.2%) | 142 (52.8%) | 0.47 (0.35 – 0.65) | 0.61 (0.43 – 0.85) |
| Hispanic (n=291, 24.7%) | 169 (58.1%) | 122 (41.9%) | 0.73 (0.54 – 1.00) | 0.91 (0.65 – 1.27) |
| Other/Unknown (n=194, 16.5%) | 110 (56.7%) | 84 (43.3%) | 0.69 (049 – 0.98) | 0.63 (0.43– 0.92) |
|
| ||||
| Smoking | ||||
| Never (n=561, 49.1%) | 349 (62.2%) | 212 (37.8%) | 1 | 1 |
| Former (n=264, 23.1%) | 157 (59.5%) | 107 (40.5%) | 0.89 (0.66 – 1.20) | 0.94 (0.68 – 1.29) |
| Current (n=317, 27.8%) | 159 (50.2%) | 158 (49.8%) | 0.61 (0.46 – 0.81) | 0.76 (0.57 – 1.02) |
|
| ||||
| HIV | ||||
| Negative (n=101, 8.6%) |
85 (84.2%) |
16 (15.8%) |
1 | 1 |
| Positive (n=756, 64.3%) | 430 (56.9%) | 326 (43.1%) | 0.25 (0.14 – 0.43) | 0.28 (0.57 – 1.02) |
| Viremic (n=318, 27.1%) | 165 (51.9%) | 153 (48.1%) | 0.20 (0.11 – 0.36) | 0.23 (0.12 – 0.43) |
|
| ||||
| CD4, Cells/mm3 | ||||
| Median 201 | 202 | 164 | - | - |
|
| ||||
| Insurance Status | ||||
| None or Public (n=763, 64.7%) | 392 (51.4%) | 371 (48.6%) | 2.23 (1.73– 2.87) | 1.83 (1.39 – 2.41) |
| Private (n=416, 35.3%) | 292 (70.2%) | 124 (29.8%) | ||
|
| ||||
| Outcome: Surveillance after Treatment | ||||
|
| ||||
| Characteristic (n=684) | No Surveillance w/in 18 months (n=510) | Surveillance w/in 18 months (n=174) | OR*** (95% CI) | Adjusted OR*** (95% CI) |
|
| ||||
| Age | ||||
| Mean (SD) 41.9 (11.4) | 42.2 (11.2) | 41.4 (12.2) | 0.96 (0.66– 1.38) | 1.09 (0.68 – 1.50) |
|
| ||||
| Sexual Practices | ||||
| †Heterosexual (n=65, 9.5%) | 48 (73.9%) | 17 (26.2%) | 1.10 (0.62 – 1.97) | 1.11 (0.59 – 2.10) |
| MSM (n=619, 90.5%) | 445 (71.9%) | 159 (28.1%) | ||
|
| ||||
| Race/Ethnicity | ||||
| †White (n=278, 40.6%) | 204 (73.4%) | 74 (26.6%) | 1 | 1 |
| Black (n=127, 18.6%) | 99 (77.2%) | 29 (22.8%) | 0.82 (0.49 – 1.34) | 0.90 (0.52 – 1.54) |
| Hispanic (n=169, 24.7%) | 120 (71.0%) | 49 (29.0%) | 1.13 (0.74 – 1.72) | 1.14 (0.72 – 1.79) |
| Other/Unknown (n=110, 16.1%) | 71 (64.6%) | 39 (34.5%) | 1.51 (0.94 – 2.43) | 1.30 (0.79 – 2.16) |
|
| ||||
| Smoking | ||||
| †Never (n=349, 52.5%) | 247 (70.8%) | 102 (29.2%) | 1 | 1 |
| Former (n=157, 23.6%) | 118 (75.2%) | 39 (24.8%) | 0.80 (0.52 – 1.23) | 0.82 (0.53 – 1.28) |
| Current (n=159, 23.9%) | 116 (73.0%) | 43 (27.0%) | 0.90 (0.59 – 1.37) | 1.0 (0.65 −1.54) |
|
| ||||
| HIV | ||||
| †Negative (n=85, 12.5%) | 53 (62.4%) | 32 (37.7%) | 1 | 1 |
| Positive (n=430, 63.2%) | 309 (71.9%) | 121 (28.1%) | 0.65 (0.40 – 1.06) | 0.68 (0.40 – 1.16) |
| Positive/Viremic (n=165, 24.3%) | 128 (77.6%) | 37 (22.4%) | 0.48 (0.27 – 0.85) | 0.52 (0.28 – 0.96) |
|
| ||||
| CD4, Cells/mm3 | ||||
| Median 202 | 203 | 201 | - | - |
|
| ||||
| Insurance Status | ||||
| †None or Public (n=392, 57.3%) | 287 (73.2.%) | 105 (26.8%) | 1.14 (0.82 – 1.60) | 1.12 (0.77 – 1.63) |
| Private (n=292, 42.7%) | 206 (70.6%) | 86 (29.5%) | ||
**
Odds ratio for HSIL treatment receipt;
***
Odds ratio for surveillance within 18 months of HSIL treatment
***
Age less then median compared to age greater then median
†
Reference category